Assessing the feasibility, toxicities and efficacy of 18-FDG PET CT guided dose optimization for radiotherapy treatment in locally advanced cervix carcinoma- A Prospective Phase 2, Pilot study - NI

The Jawaharlal Institute of Postgraduate Medical Education Research0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1. Treatment naïve,
•2. histopathologically proven carcinoma cervix (squamous/adeno/adeno-squamous),
•3. International Federation of Gynecology and Obstetrics (FIGO) (2018) stage 1B-IIIC2 patients,
•4. age 18-60 years,
•5. attending gynecological tumor clinics, with ECOG performance status 0-2,
•6. with adequate organ function and planned for definitive treatment with chemoradiotherapy and intracavitary brachytherapy.
•7. Adequate organ function at time of participation

•1. Patients with uncontrolled Diabetes mellitus, hypertension
•2. Patients with HIV infection, Hepatitis B/C infection/ Active Tuberculosis/ any other systemic infection
•3. Previously any pelvic surgery / partial or total hysterectomy
•4. Previous pelvic/ abdominal radiotherapy
•5. Patients with history of neoadjuvant chemotherapy
•6. Patients with history of allergy to iodinated contrast or 18F-FDG
•7. Patients requiring ISBT post external beam radiotherapy treatment
•8. Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin
•9. Pregnancy
•10. Patients with bladder or rectal invasion at diagnosis, vesico-vaginal fistula, or recto-vaginal fistula at diagnosis or post EBRT

发起方

The Jawaharlal Institute of Postgraduate Medical Education Research